The HIV diagnostics test market is estimated to be valued at US$ 14.05 Mn in 2023 and is expected to exhibit a CAGR of 9.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
HIV diagnostics tests are utilized to detect the presence of Human Immunodeficiency Virus (HIV) that causes AIDS in human body. These tests can detect HIV infection within a few weeks after exposure to the virus in an individual's blood and oral fluids. The mainstream products available in the market are HIV test kits, analyzers and reagents.

Market Dynamics:
The HIV diagnostics test market is witnessing high growth owing to growing government initiatives for creating awareness about HIV infection and its preventive measures. According to United Nations Program on HIV/AIDS (UNAIDS), around 75% of the population in developed countries are aware of their HIV status. However, in developing nations, nearly 30% of the people living with HIV are unaware of their infection status. To curb this, various governments across globe are launching awareness programs and making diagnostic tests more accessible to people. Additionally, the emergence of advanced testing technologies such as 4th generation HIV diagnostic kits that can detect both antibodies and antigens is also boosting early detection of HIV. However, lack of healthcare infrastructure and medical staff in underdeveloped regions may restrain the market growth.

SWOT Analysis
Strength: HIV diagnostics test have high accuracy and sensitivity which helps in early detection of HIV. Rapid HIV tests provide results within 20 minutes which is convenient for patients. Development of novel platforms like PCR and western blot have improved detection window period.
Weakness: High cost of advanced HIV diagnostic kits limits their use in low and middle income countries. Lack of awareness in developing nations results in delayed testing. Complex procedures of few diagnostic techniques requires trained healthcare professionals.
Opportunity: Rising public-private partnerships and government initiatives aiming to control the HIV epidemic worldwide presents new opportunities. Growing health investments in emerging nations will boost market growth. Point of care testing can increase testing rates in remote locations.
Threats: Stringent regulatory approvals and post marketing surveillance increases complexity. Social stigma and cultural taboos around HIV/AIDS continues to be a challenge. Emergence of newer pathogens may divert healthcare investments.

Key Takeaways
The Global HIV Diagnostics Test Market Size is expected to witness high growth, exhibiting CAGR of 9.0% over the forecast period, due to increasing prevalence of HIV infections globally. North America dominates the market currently due to growing awareness initiatives to curb the epidemic. However, Asia Pacific is expected to witness fastest growth during the forecast period owing to rising healthcare expenditures and large population base in countries such as India and China.

Regional analysis Asia Pacific is expected to grow at the fastest rate over the forecast period due to the high unmet needs, increasing number of diagnostic tests performed, and rising awareness about HIV diagnostics in major Asian countries. Several government initiatives to spread awareness about HIV/AIDS have augmented the growth of the market in the region.

Key players operating in the HIV Diagnostics Test market are Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol €“Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.

Read more: https://journaljourney32.weebly.com/hiv-diagnostics-test-market